Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marion Tonneau

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Scientific Reports|July 8, 2023
Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional studySevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, et al.
JTO Clinical and Research Reports|December 21, 2023
Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional StudySevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 11, 2023
A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapyMarion Tonneau, Corentin Richard, Bertrand Routy, et al.
Cancer Treatment and Research Communications|October 13, 2023
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapyFrancis Proulx-Rocray, Bertrand Routy, Rami Nassabein, et al.
Cancers|February 24, 2024
CXCL13 Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non-Small Cell CarcinomaFatemeh Vahidian, Fabien C Lamaze, Cédrik Bouffard, et al.
Cancers|August 12, 2023
A Radiomics-Clinical Model Predicts Overall Survival of Non-Small Cell Lung Cancer Patients Treated with Immunotherapy: A Multicenter StudySevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, et al.
Cancers|January 23, 2024
The Cross-Scale Association between Pathomics and Radiomics Features in Immunotherapy-Treated NSCLC Patients: A Preliminary StudyAbdou Khadir Dia, Leyla Ebrahimpour, Sevinj Yolchuyeva, et al.
Clinical and Translational Radiation Oncology|March 4, 2022
<b>S</b>tereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)Houda Bahig, Marion Tonneau, Normand Blais, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 12, 2025
Radiotherapy for lung metastasesAntonin Levy, Marion Tonneau, Julien Darréon, et al.
Journal of Translational Medicine|May 6, 2025
Computational analysis of whole slide images predicts PD-L1 expression and progression-free survival in immunotherapy-treated non-small cell lung cancer patientsAbdou Khadir Dia, Alona Kolnohuz, Sevinj Yolchuyeva, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Scientific Reports|July 8, 2023
Radiomics approaches to predict PD-L1 and PFS in advanced non-small cell lung patients treated with immunotherapy: a multi-institutional studySevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, et al.
JTO Clinical and Research Reports|December 21, 2023
Imaging-Based Biomarkers Predict Programmed Death-Ligand 1 and Survival Outcomes in Advanced NSCLC Treated With Nivolumab and Pembrolizumab: A Multi-Institutional StudySevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 11, 2023
A competing risk analysis of the patterns and risk factors of recurrence in early-stage non-small cell lung cancer treated with stereotactic ablative radiotherapyMarion Tonneau, Corentin Richard, Bertrand Routy, et al.
Cancer Treatment and Research Communications|October 13, 2023
The prognostic impact of KRAS, TP53, STK11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapyFrancis Proulx-Rocray, Bertrand Routy, Rami Nassabein, et al.
Cancers|February 24, 2024
CXCL13 Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non-Small Cell CarcinomaFatemeh Vahidian, Fabien C Lamaze, Cédrik Bouffard, et al.
Cancers|August 12, 2023
A Radiomics-Clinical Model Predicts Overall Survival of Non-Small Cell Lung Cancer Patients Treated with Immunotherapy: A Multicenter StudySevinj Yolchuyeva, Elena Giacomazzi, Marion Tonneau, et al.
Cancers|January 23, 2024
The Cross-Scale Association between Pathomics and Radiomics Features in Immunotherapy-Treated NSCLC Patients: A Preliminary StudyAbdou Khadir Dia, Leyla Ebrahimpour, Sevinj Yolchuyeva, et al.
Clinical and Translational Radiation Oncology|March 4, 2022
<b>S</b>tereotactic Ablative Radiotherapy for oligo-progressive disease refractory to systemic therapy in Non-Small Cell Lung Cancer: A registry-based phase II randomized trial (SUPPRESS-NSCLC)Houda Bahig, Marion Tonneau, Normand Blais, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 12, 2025
Radiotherapy for lung metastasesAntonin Levy, Marion Tonneau, Julien Darréon, et al.
Journal of Translational Medicine|May 6, 2025
Computational analysis of whole slide images predicts PD-L1 expression and progression-free survival in immunotherapy-treated non-small cell lung cancer patientsAbdou Khadir Dia, Alona Kolnohuz, Sevinj Yolchuyeva, et al.
Pageof 3